Product launch Summa Therapeutics recently launched an injectable balloon catheter targeting below-the-knee peripheral artery disease, presenting a clear sales opportunity to vascular surgeons, hospitals, and medical centers specializing in leg revascularization.

Strategic redesign A redesigned product line rolled out in 2024 with planned U.S. and select international market launches offers cross-selling potential to existing customers and a chance to upsell complementary catheter technologies and related accessories.

Early stage funding With current revenue under a million dollars and a lean team, there is a need for scaled manufacturing, quality assurance, and distribution partnerships to accelerate growth and capture market share in peripheral intervention devices.

Regional expansion The company’s Cambridge, MA location and ambitious global rollout imply opportunities for regional distributors, clinical training programs, and aftersales support agreements in the U.S. and select markets worldwide.

Market positioning As a medical equipment innovator focused on efficiency, safety, and economic benefits in leg revascularization, Summa can be a compelling partner for hospitals seeking cost-effective devices that improve procedure outcomes and reduce hospital stay durations.